A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis

Status unconfirmed · Phase 1

Conditions studied: Multiple Sclerosis

In brief

A Phase I Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis to demonstrate safety \& efficacy

Key facts

Study ID

NCT02200718

Run by

Immune Response BioPharma, Inc.

People needed

12

Starts

2020-12-31

Expected to finish

2024-11-09

Last updated by the study team

2020-03-31

Who can join

Age: 5 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ages Eligible for Study: 5 Years to 17 Years
• Genders Eligible for Study: Both
• Accepts Healthy Volunteers: No Criteria
• Subject is between 5 and 17 years of age, inclusive
• Clinically diagnosed Pediatric MS
• Definite Pediatric MS by the revised McDonald criteria (2005) (Appendix A), with a pediatric MS course
• Expanded Disability Status Scale (EDSS) <= score 6.5 (Appendix B) Two or more documented clinical relapses of MS in the preceding 24 months OR one documented clinical relapse of MS in the preceding 12 months prior to screening
• Laboratory values within the following limits:
• Creatinine 1 . 5 x high normal
• Hemoglobin

You may not qualify if…

• Subjects currently prescribed Campath or Lemtrada

Where it is running

• CRO — San Diego, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.